Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Enanta Pharmaceuticals (ENTA) EBT (2016 - 2025)

Enanta Pharmaceuticals' EBT history spans 14 years, with the latest figure at -$11.9 million for Q4 2025.

  • For Q4 2025, EBT rose 47.53% year-over-year to -$11.9 million; the TTM value through Dec 2025 reached -$72.8 million, up 31.66%, while the annual FY2025 figure was -$83.5 million, 29.07% up from the prior year.
  • EBT reached -$11.9 million in Q4 2025 per ENTA's latest filing, up from -$18.7 million in the prior quarter.
  • In the past five years, EBT ranged from a high of -$11.9 million in Q4 2025 to a low of -$37.6 million in Q1 2023.
  • Average EBT over 5 years is -$28.1 million, with a median of -$29.4 million recorded in 2023.
  • Peak YoY movement for EBT: tumbled 193.75% in 2021, then skyrocketed 47.53% in 2025.
  • A 5-year view of EBT shows it stood at -$30.2 million in 2021, then increased by 3.75% to -$29.0 million in 2022, then decreased by 17.26% to -$34.0 million in 2023, then surged by 33.27% to -$22.7 million in 2024, then surged by 47.53% to -$11.9 million in 2025.
  • Per Business Quant, the three most recent readings for ENTA's EBT are -$11.9 million (Q4 2025), -$18.7 million (Q3 2025), and -$18.2 million (Q2 2025).